ZYNE earnings

PLYMOUTH MEETING, Pa. and DEVON, Pa., Aug. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE), a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS). Under the terms of the definitive agreement, Harmony

– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments – – Safety data reinforce excellent tolerability profile of Zygel – – Company will focus resources on FXS and 22q development – – Cash runway extended through the end of 2023 / early 2024 – – Zynerba to host conference call and webcast tomorrow, June 22, 2022 at 9:00 a.m. ET – DEVON, Pa., June 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced positive top line results from the explorat

– Company plans to focus development of Zygel™ in FXS, ASD and 22q – – Company plans to initiate Phase 3 trial with Zygel in ASD in the second half of 2022 – – Zynerba to hold conference call tomorrow, January 5, 2022 at 9:00 a.m. ET – DEVON, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today provided program updates for Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q) and developmental and epileptic encephalopathies (DEE). In addition to the continued clinical development o